Clinical Trial Detail

NCT ID NCT01769209
Title Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Stanford University
Indications

acute lymphoblastic leukemia

Therapies

Bortezomib

Cytarabine + Methotrexate

Dexamethasone + Doxorubicin + Pegaspargase + Vincristine Sulfate

Age Groups: adult

No variant requirements are available.